Union Calendar No. 196

112TH CONGRESS
1ST SESSION

H. R. 1254

[Report No. 112–295, Parts I and II]

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

IN THE HOUSE OF REPRESENTATIVES

MARCH 30, 2011

Mr. Dent (for himself, Mr. Meehan, Mr. Marino, Mr. Platts, Mr. Barletta, Mr. Cuellar, Mrs. Emerson, Mrs. Biggert, Mr. LaTourette, Mr. Gibson, Mr. Stivers, and Mr. Reed) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

NOVEMBER 22, 2011

Reported from the Committee on Energy and Commerce with an amendment

[Strike out all after the enacting clause and insert the part printed in italic]

NOVEMBER 22, 2011

Additional sponsors: Mr. Holden, Mr. Boswell, Mr. Latham, Mr. Loeb, Mr. DeFazio, Mr. Dold, Mr. Lance, Mr. Murphy of Pennsylvania, Mrs. Bono Mack, Mr. Michaud, Ms. Pingree of Maine, and Mr. Gowdy

NOVEMBER 22, 2011

Reported from the Committee on the Judiciary with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed

[Strike out all after the enacting clause and insert the part printed in boldface roman]

[For text of introduced bill, see copy of bill as introduced on March 30, 2011]
A BILL

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Synthetic Drug Control
Act of 2011”.

SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I

OF THE CONTROLLED SUBSTANCES ACT.

(a) CANNABIMIMETIC AGENTS.—Schedule I, as set
forth in section 202(c) of the Controlled Substances Act (21
U.S.C. 812(c)) is amended by adding at the end the fol-
lowing:

“(d)(1) Unless specifically exempted or unless listed in
another schedule, any material, compound, mixture, or
preparation which contains any quantity of
cannabimimetic agents, or which contains their salts, is-
omers, and salts of isomers whenever the existence of such
salts, isomers, and salts of isomers is possible within the
specific chemical designation.

“(2) In paragraph (1):

“(A) The term ‘cannabimimetic agents’ means
any substance that is a cannabinoid receptor type 1
(CB1 receptor) agonist as demonstrated by binding
studies and functional assays within any of the fol-
lowing structural classes:
“(i) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.

“(ii) 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.

“(iii) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.

“(iv) 1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.

“(v) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.
“(B) Such term includes—

“(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);

“(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabinol
or CP-47,497 C8-homolog);

“(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678);

“(iv) 1-butyl-3-(1-naphthoyl)indole (JWH-073);

“(v) 1-hexyl-3-(1-naphthoyl)indole (JWH-019);

“(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

“(vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);

“(viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);

“(ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

“(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

“(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
“(xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);
“(xiii) 1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4);
“(xiv) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8); and
“(xv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).”

(b) OTHER DRUGS.—Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:
“(18) 4-methylmethcathinone (Mephedrone).
“(19) 3,4-methylenedioxypyrovalerone (MDPV).
“(20) 3,4-methylenedioxymethcathinone (methylone).
“(21) Naphthylpyrovalerone (naphyrone).
“(22) 4-fluoromethcathinone (flephedrone).
“(23) 4-methoxymethcathinone (methedrone; Bk-PMMA).
“(24) Ethcathinone (N-Ethylcathinone).
“(25) 3,4-methylenedioxyethylcathinone (ethylone).
“(26) Beta-keto-N-methyl-3,4-benzodioxylybutanamine (butylone).
“(27) N,N-dimethylcathinone (metamfepramone).
“(28) Alpha-pyrrolidinopropiophenone (alpha-
PPP).

“(29) 4-methoxy-alpha-pyrrolidinopropiophenone
(MOPPP).

“(30) 3,4-methylenedioxy-alpha-
pyrrolidinopropiophenone (MDPPP).

“(31) Alpha-pyrrolidinovalerophenone (alpha-
PVP).

“(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-
6-amine) (MDAI).

“(33) 3-fluoromethcathinone.

“(34) 4’-Methyl-α-pyrrolidinobutiophenone
(MPBP).”.

SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT
HAZARDS TO PUBLIC SAFETY EXPANSION.

Section 201(h)(2) of the Controlled Substances Act (21
U.S.C. 811(h)(2)) is amended—

(1) by striking “one year” and inserting “2
years”; and

(2) by striking “six months” and inserting “1
year”.

SECTION 1. SHORT TITLE.

This Act may be cited as the “Synthetic
Drug Control Act of 2011”.

•HR 1254 RH
SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I
OF THE CONTROLLED SUBSTANCES ACT.

(a) CANNABIMIMETIC AGENTS.—Schedule I, as set forth in section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at the end the following:

“(d)(1) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

“(2) In paragraph (1):

“(A) The term ‘cannabimimetic agents’ means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:

“(i) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl,
whether or not substituted on the cyclohexyl ring to any extent.

“(ii) 3-(1-naphthoyl)indole or 3-(1-naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.

“(iii) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.

“(iv) 1-(1-naphthylmethylen)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.
“(v) 3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.

“(B) Such term includes—

“(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP–47,497);

“(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog);

“(iii) 1-pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678);

“(iv) 1-butyl-3-(1-naphthoyl)indole (JWH–073);

“(v) 1-hexyl-3-(1-naphthoyl)indole (JWH–019);

“(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200);
“(vii) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250);
“(viii) 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081);
“(ix) 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122);
“(x) 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398);
“(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
“(xii) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);
“(xiii) 1-pentyl-3-[(4-methoxy)benzoyl]indole (SR–19 and RCS–4);
“(xiv) 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8); and
“(xv) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH–203).”.

(b) OTHER DRUGS.—Schedule I of section 202(c) of the Controlled Substances Act (21 U.S.C. 812(c)) is amended in subsection (c) by adding at the end the following:
“(18) 4-methylmethcathinone (Mephedrone).

“(19) 3,4-methylenedioxyethylcathinone (MDPV).

“(20) 3,4-methylenedioxyethylcathinone (methylone).

“(21) Naphthalpyrovalerone (naphyrone).

“(22) 4-fluoromethcathinone (flephedrone).

“(23) 4-methoxymethcathinone (methedrone; Bk–PMMA).

“(24) Ethcathinone (N-Ethylcathinone).

“(25) 3,4-methylenedioxyethylcathinone (ethylone).

“(26) Beta-keto-N-methyl-3,4-benzodioxyolbutanamine (butylone).

“(27) N,N-dimethylcathinone (metamfepramone).

“(28) Alpha-pyrrolidinopropiophenone (alpha-PPP).

“(29) 4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP).
“(30) 3,4-methylenedioxy-
alphapyrrolidinopropiophenone
(MDPPP).

“(31) Alpha-pyrrolidinovalerophenone
(alpha-PVP).

“(32) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-
dioxol-6-amine) (MDAI).

“(33) 3-fluoromethcathinone.

“(34) 4’-Methyl-\(\alpha\)-
pyrrolidinobutiophenone (MPBP).

“(35) 2-(2,5-Dimethoxy-4-
ethylphenyl)ethanamine (2C–E).

“(36) 2-(2,5-Dimethoxy-4-
methylphenyl)ethanamine (2C–D).

“(37) 2-(4-Chloro-2,5-
dimethoxyphenyl)ethanamine (2C–C).

“(38) 2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine (2C–I).

“(39) 2-[4-(Ethylthio)-2,5-

“(40) 2-[4-(Isopropylthio)-2,5-

“(41) 2-(2,5-
Dimethoxyphenyl)ethanamine (2C–H).
“(42) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C–N).
“(43) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P).”.

SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT HAZARDS TO PUBLIC SAFETY EXPANSION.

Section 201(h)(2) of the Controlled Substances Act (21 U.S.C. 811(h)(2)) is amended—
(1) by striking “one year” and inserting “2 years”; and
(2) by striking “six months” and inserting “1 year”.

•HR 1254 RH
A BILL

To amend the Controlled Substances Act to place synthetic drugs in Schedule I.

November 22, 2011

Reported from the Committee on Energy and Commerce

Reported from the Committee on the Judiciary with an amendment

November 22, 2011

Ordered to be printed